BSE filing, NSE: GODAVARI. Summary written from the filing by ALFA Finder's alert engine.
Godavari Drugs Ltd: key numbers
- Share price
- ₹121.00
- Market cap
- ₹122.5 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 29.5×Sector 46.1×
- Promoter holding
- 40.23%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Other Announcement
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Debt & Borrowing: ₹34 Cr
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
- Value
- ₹34.00 Cr
Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Annual General Meeting
Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.
Godavari Drugs Board Meeting Outcome
Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.
Godavari Drugs Capital Structure Change
Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.
- Value
- ₹5.25 Cr
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.